THREE-YEAR FOLLOW-UP OF A PILOT STUDY OF RANIBIZUMAB COMBINED WITH PROTON BEAM IRRADIATION AS TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Authors:
- Inder DaftariIDInder Daftari
- Theodore PhillipsTPTheodore Phillips
- Lawrence S. MorseLMLawrence S. Morse
- 1 May 2012
- journal article
- Published by Wolters Kluwer Health in Retina
- Vol. 32 (5) , 956-966
Abstract
To investigate the safety and tolerability of ranibizumab combined with proton beam irradiation in treating exudative age-related macular degeneration. Six eyes (6 subjects) with exudative age-related macular degeneration (4 newly diagnosed; 2 previous treated with ranibizumab) were treated with 4 monthly ranibizumab and 24 GyE proton beam irradiation (2 fractions, 24 hours apart) and seen monthly thereafter and retreated with ranibizumab for decrease in best-corrected visual acuity of ≥2 lines, new macular hemorrhage or fluid noted on optical coherence tomography. Follow-up ranged from 12 months to 36 months (mean, 28 months). Baseline best-corrected visual acuity ranged from 20/40 to 20/250. Final best-corrected visual acuity ranged from 20/25 to 20/400. No radiation retinopathy was noted in any eye. Calculated radiation distribution dose curves indicate that ≤10% of retina received ≥90% of radiation dose in all eyes. Two subjects lost ≥3 lines of best-corrected visual acuity during follow-up, 1 subject in both eyes from enlarging geographic atrophy and the other from worsening fibrovascular pigment epithelial detachment, which was refractory to multiple ranibizumab treatments before enrollment. Among 4 eyes with newly diagnosed exudative age-related macular degeneration, 3 had no fluid on optical coherence tomography at month 12 without further treatment. No safety concerns were noted after 3 years in eyes with exudative age-related macular degeneration treated with ranibizumab combined with proton beam irradiation in this small pilot study. A larger randomized prospective study is under way to further evaluate this combination therapy.Keywords
This publication has 22 references indexed in Scilit:
- Comparative Evaluation of Apoptotic Activity in Photoreceptor Cells after Intravitreal Injection of Bevacizumab and Pegaptanib Sodium in RabbitsInvestigative Ophthalmology & Visual Science, 2009
- Vitreomacular Adhesion in Active and End-Stage Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2009
- Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degenerationBritish Journal of Ophthalmology, 2008
- Radiation Retinopathy Is Treatable With Anti–Vascular Endothelial Growth Factor Bevacizumab (Avastin)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Proton Beam Irradiation for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Tumor angiogenesis and accessibility: Role of vascular endothelial growth factorSeminars in Oncology, 2002
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyArchives of Ophthalmology (1950), 1984